Footnotes, Table 5.6.6-A 
1 During the AdCFTR experimental therapy period, all adverse reactions will be 
reported along with the clinical and laboratory assessment as to whether the 
adverse reaction is associated with the AdCFTR vector, the procedure used to 
assess safety or efficacy, or an intercurrent illness. 
2 Marked increase in white blood counts with an increase in percent neutrophils is 
frequent in individuals with cystic fibrosis following bronchoscopy. Fever of 
39-40° is also frequent. 
3 Despite vitamin K therapy 
* Above baseline 
5 Above baseline for grades I - III 
6 For greater than 6 hours despite antipyretic therapy 
7 Lung function tests, including forced vital capacity and forced expiratory 
volume in 1 second 
[760] 
Recombinant DNA Research, Volume 16 
